The present invention relates to a method for providing information on a diagnosis or prognostic measurement of the histological severity of nonalcoholic fatty liver disease. Since the risk associated with the severity of nonalcoholic fatty liver disease can be considered to have increased when the content of sphingomyelin is at least 1.3 times higher than in a normal control group, the present invention can be effectively used for the diagnosis or prognostic measurement of severity.

The present disclosure relates to methods and uses involving the determination of lipid concentrations in order to diagnose, predict, prevent and/or treat one or more cardiovascular events in a subject. The methods include analyzing lipid concentrations of a sample from the subject and comparing them to a control.

The present invention relates to methods for diagnosing Respiratory Distress Syndrome of newborn.

This disclosure provides a use of biomarker SM(d18:1/24:1(15Z)) in the preparation of a reagent or kit for diagnosing cognitive impairment. This disclosure also provides a method for diagnosing and treating cognitive impairment by detecting the content of biomarkers SM(d18:1/24:1(15Z)) and TG(16:0/18:0/18:4(6Z,9Z,12Z,15Z)), PC(P-16:0/22:4(7Z,10Z,13Z,16Z) or PC(P-18:0/18:4(6Z,9Z,12Z,15Z)) to determine whether the patient has cognitive impairment.

This disclosure provides a method for diagnosing the action of nervonic acid and use thereof. The method for diagnosing acting of nervonic acid in acer truncatum bunge seed oil can be used to determine whether nervonic acid is absorbed and transformed by the body, and provides guidance for whether nervonic acid plays a role after intaking acer truncatum bunge seed oil.

Provided are methods and related kits for detection of early stage prostate cancer, and determination of risk of being at risk for progression of prostate cancer.

Disclosed are various lipid biomarkers of inflammatory bowel disease, including biomarkers for inflammatory bowel diseases including Crohn’s disease and Ulcerative colitis. Also disclosed are various biomarkers of disease location and/or disease behavior in inflammatory bowel disease. The present disclosure also provides methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, and methods of assessing efficacy of compositions for treating inflammatory bowel disease.

The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

The present invention relates to a novel analytical method for detecting one or more analytes in a source sample by continuous flow 2D LC-MS/MS using a single LC system.

A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed comprising: (a) using a first device to generate smoke, aerosol or vapour from a target in vitro or ex vivo cell population; (b) mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and (c) analysing said spectrometric data in order to identify and/or characterise said target cell population or one or more cells and/or compounds present in said target cell population.